Norway, Aug. 13 -- Lifecare ASA (LIFE), a MedTech company developing next-generation Continuous Glucose Monitoring (CGM) technology for diabetes management, is pleased to announce that formal preparations towards CE marking of its CGM as a fully regulated medical device have been underway for the past six weeks.Lifecare has started the formal preparations to document regulatory compliance and achieve CE mark for its CGM system as a fully regulated medical device, according to our communicated plan, by end of 2026. This phase encompasses the full CGM system - sensor, implant, reader, manufacturing processes, and comprehensive ISO 13485-compliant documentation, the international recognised quality standard for medical devices - firmly placing...